Navigation Links
Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Date:3/10/2008

PINE BROOK, N.J., March 10 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced the appointment of Robert Gundel, Ph.D., M.B.A., as Vice President of Research.

Elizabeth G. Posillico, Ph.D., President and Chief Executive Officer, commented on the appointment, "On behalf of Elusys' Board of Directors and management, I am very pleased to welcome Bob to our executive management team. As Vice President of Research, he will play a key role in helping to further develop and advance our corporate and scientific strategies. With more than twenty-five years of experience in developing monoclonal antibody-based products from both the biotech and pharmaceutical sectors, Dr. Gundel will lead our existing R&D team to further the development of our antibody based products for the treatment of infectious disease. He will also use his expertise to evaluate new product opportunities and will play a key leadership role in managing our existing and future R&D collaborations."

Prior to joining Elusys, Dr. Gundel held executive management positions at a number of leading biopharmaceutical companies including, Bayer, Chiron, XOMA and ARIUS. Most recently, Dr. Gundel served as Chief Scientific Officer at ARIUS Research, Inc., a biotechnology company focused on the discovery and development of therapeutic antibodies for the treatment of cancer and other diseases. At ARIUS, he managed the drug discovery and development programs and worked to broaden the company's targeted therapeutic areas by identifying and developing new programs outside of oncology. He also identified new technologies to keep the company ahead of the curve for therapeutic drug discovery, development and manufacturing.

Previously, Dr. Gundel was Vice President, Preclinical Research and Scientific Corporate Development at XOMA (US), LLC, a biotechnology company specializing in the discovery, development and manufacturing of therapeutic antibodies. At XOMA, he directed preclinical research and coordinated discovery and development activities in a number of therapeutic areas, including infectious diseases, inflammatory disorders and cancer.

Dr. Gundel also served as Vice President, Pharmacology and Preclinical Research at Chiron Corporation, where he supervised efforts to identify and characterize novel therapeutics for inflammatory diseases. Earlier, Dr. Gundel worked at Bayer Corporation where he held various positions within the Biotechnology Unit including Director of Pharmacology. He began his career in pharmaceutical R&D at Boehringer Ingelheim Pharmaceuticals, Inc., where he supervised efforts to identify and characterize novel therapeutics for inflammatory diseases.

Dr. Gundel earned his M.B.A. from Saint Mary's College, and his Ph.D. in physiology from New York Medical College. He has participated in over 45 national and international scientific meetings as an invited speaker and/or session chairperson. He has published more than 60 articles in peer reviewed journals and book chapters, served on the editorial board of several journals and is a co-inventor on several issued U.S. patents.

About Elusys

Elusys is a privately held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life- threatening infectious diseases. In March of 2007, the company's anthrax antibody therapeutic, Anthim, was selected to R&D Directions' list of "100 Great Investigational Drugs." Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
2. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
3. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
4. ExonHit Therapeutics - 2007 Financial Results
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
7. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
8. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
9. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
10. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
11. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):